WallStSmart

Accendra Health Inc (ACH)vsEDAP TMS SA (EDAP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Accendra Health Inc generates 3567% more annual revenue ($2.72B vs $74.07M). ACH leads profitability with a -39.8% profit margin vs -41.7%. ACH appears more attractively valued with a PEG of 0.70. ACH earns a higher WallStSmart Score of 44/100 (D).

ACH

Hold

44

out of 100

Grade: D

Growth: 2.7Profit: 2.5Value: 7.7Quality: 4.5
Piotroski: 2/9Altman Z: 0.52

EDAP

Avoid

25

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACHUndervalued (+71.5%)

Margin of Safety

+71.5%

Fair Value

$8.34

Current Price

$2.70

$5.64 discount

UndervaluedFair: $8.34Overvalued
EDAPUndervalued (+41.7%)

Margin of Safety

+41.7%

Fair Value

$8.41

Current Price

$4.31

$4.10 discount

UndervaluedFair: $8.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACH2 strengths · Avg: 9.0/10
Debt/EquityHealth
-4.6710/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.708/10

Growing faster than its price suggests

EDAP0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ACH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$217.50M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-198.4%2/10

ROE of -198.4% — below average capital efficiency

EDAP4 concerns · Avg: 2.8/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Market CapQuality
$156.30M3/10

Smaller company, higher risk/reward

PEG RatioValuation
90.472/10

Expensive relative to growth rate

Return on EquityProfitability
-124.0%2/10

ROE of -124.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ACH

The strongest argument for ACH centers on Debt/Equity, PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.

Bull Case : EDAP

Revenue growth of 13.9% demonstrates continued momentum.

Bear Case : ACH

The primary concerns for ACH are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : EDAP

The primary concerns for EDAP are Price/Book, Market Cap, PEG Ratio.

Key Dynamics to Monitor

ACH carries more volatility with a beta of 1.70 — expect wider price swings.

EDAP is growing revenue faster at 13.9% — sustainability is the question.

EDAP generates stronger free cash flow (-4M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ACH scores higher overall (44/100 vs 25/100). EDAP offers better value entry with a 41.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accendra Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Aluminum Corporation of China Limited, manufactures and sells alumina, primary aluminum and energy products in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

EDAP TMS SA

HEALTHCARE · MEDICAL DISTRIBUTION · USA

EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.

Want to dig deeper into these stocks?